异动解读 | 百济神州盘中大涨逾5% 或受FDA会议信号利好刺激

异动解读09-27

9月27日,百济神州(688235)股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。

据悉,FDA此次会议的核心议题是讨论是否应根据PD-L1蛋白表达水平来限制PD-1/L1单抗在胃癌和食管鳞癌治疗中的适用范围。会议投票结果显示,对于PD-L1表达较低(<1或<10)的患者,使用PD-1抑制剂作为一线治疗的风险可能大于收益。

百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。不过会议投票结果并未建议对所有患者使用PD-1抑制剂做出严格限制,市场预期影响有限。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

唤唤霸霸
09-27
唤唤霸霸
……什么原因不知道？找的什么毛消息

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1167257338?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-27 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167257338","market":"us","top_or_hot":-1,"title":"异动解读 | 百济神州盘中大涨逾5% 或受FDA会议信号利好刺激","media":"异动解读","content":"<p>9月27日,百济神州(688235)股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。</p>\n\n<p>据悉,FDA此次会议的核心议题是讨论是否应根据PD-L1蛋白表达水平来限制PD-1/L1单抗在胃癌和食管鳞癌治疗中的适用范围。会议投票结果显示,对于PD-L1表达较低(<1或<10)的患者,使用PD-1抑制剂作为一线治疗的风险可能大于收益。</p>  \n\n<p>百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。不过会议投票结果并未建议对所有患者使用PD-1抑制剂做出严格限制,市场预期影响有限。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 百济神州盘中大涨逾5% 或受FDA会议信号利好刺激</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 百济神州盘中大涨逾5% 或受FDA会议信号利好刺激\n</h2>\n\n<h4 class=\"meta\">\n\n2024-09-27 22:10 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月27日,百济神州(688235)股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。\n据悉,FDA此次会议的核心议题是讨论是否应根据PD-L1蛋白表达水平来限制PD-1/L1单抗在胃癌和食管鳞癌治疗中的适用范围。会议投票结果显示,对于PD-L1表达较低(<1或<10)的...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BGNE","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1167257338","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167257338","pubTimestamp":1727446225,"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"9月27日,百济神州股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BGNE":"百济神州"},"translate_title":"Interpretation of the change: BeiGene rose more than 5% in intraday trading, which may be stimulated by positive signals from the FDA meeting","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1},"content_text":"9月27日,百济神州(688235)股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。\n据悉,FDA此次会议的核心议题是讨论是否应根据PD-L1蛋白表达水平来限制PD-1/L1单抗在胃癌和食管鳞癌治疗中的适用范围。会议投票结果显示,对于PD-L1表达较低(<1或<10)的患者,使用PD-1抑制剂作为一线治疗的风险可能大于收益。\n百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。不过会议投票结果并未建议对所有患者使用PD-1抑制剂做出严格限制,市场预期影响有限。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":354075024097448,"gmtCreate":1727452280695,"gmtModify":1727452285847,"author":{"id":"3547499860800538","authorId":"3547499860800538","name":"唤唤霸霸","avatar":"https://static.tigerbbs.com/4842950dc96000bc44fa266137eef860","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3547499860800538","idStr":"3547499860800538"},"htmlText":"……什么原因不知道？找的什么毛消息","listText":"……什么原因不知道？找的什么毛消息","text":"……什么原因不知道？找的什么毛消息","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354075024097448","repostId":1167257338,"repostType":2,"repost":{"id":"1167257338","weMediaInfo":{"introduction":"个股异动一手消息解读","home_visible":1,"media_name":"异动解读","id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1727446225,"share":"https://www.laohu8.com/m/news/1167257338?lang=&edition=full","pubTime":"2024-09-27 22:10","market":"us","language":"zh","title":"异动解读 | 百济神州盘中大涨逾5% 或受FDA会议信号利好刺激","url":"https://stock-news.laohu8.com/highlight/detail?id=1167257338","media":"异动解读","summary":"9月27日,百济神州股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。","content":"<p>9月27日,百济神州(688235)股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。</p>\n\n<p>据悉,FDA此次会议的核心议题是讨论是否应根据PD-L1蛋白表达水平来限制PD-1/L1单抗在胃癌和食管鳞癌治疗中的适用范围。会议投票结果显示,对于PD-L1表达较低(<1或<10)的患者,使用PD-1抑制剂作为一线治疗的风险可能大于收益。</p>  \n\n<p>百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。不过会议投票结果并未建议对所有患者使用PD-1抑制剂做出严格限制,市场预期影响有限。</p>","source":"ai_movement_cn","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 百济神州盘中大涨逾5% 或受FDA会议信号利好刺激</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 百济神州盘中大涨逾5% 或受FDA会议信号利好刺激\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2024-09-27 22:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>9月27日,百济神州(688235)股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。</p>\n\n<p>据悉,FDA此次会议的核心议题是讨论是否应根据PD-L1蛋白表达水平来限制PD-1/L1单抗在胃癌和食管鳞癌治疗中的适用范围。会议投票结果显示,对于PD-L1表达较低(<1或<10)的患者,使用PD-1抑制剂作为一线治疗的风险可能大于收益。</p>  \n\n<p>百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。不过会议投票结果并未建议对所有患者使用PD-1抑制剂做出严格限制,市场预期影响有限。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGNE":"百济神州"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167257338","content_text":"9月27日,百济神州(688235)股价盘中大涨逾5%,引发市场关注。分析人士指出,此前美国FDA就PD-1抑制剂获批适应症限制一事召开了肿瘤药物咨询委员会会议,会议投票结果或成为利好信号,刺激了百济神州股价上涨。\n据悉,FDA此次会议的核心议题是讨论是否应根据PD-L1蛋白表达水平来限制PD-1/L1单抗在胃癌和食管鳞癌治疗中的适用范围。会议投票结果显示,对于PD-L1表达较低(<1或<10)的患者,使用PD-1抑制剂作为一线治疗的风险可能大于收益。\n百济神州的PD-1抑制剂产品替雷利珠单抗已在全球多个市场获批上市,如果FDA最终决定修改标签,从适应症中剔除PD-L1低表达患者,可能会在一定程度上影响其全球销售业绩。不过会议投票结果并未建议对所有患者使用PD-1抑制剂做出严格限制,市场预期影响有限。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167257338"}